Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab plus chemotherapy in first-line metastatic squamous NSCLC
NCT03866993Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Dec 2018
- Primary completion
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of penpulimab in squamous cell carcinoma of the lung (SCCL), sponsored by Akeso, Inc.. Started Dec 2018; status: completed.
02
Drugs
penpulimab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT03866993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866993.